PCSA vs. RNAZ, IBIO, SHPH, TENX, PULM, CANF, KTTA, UPC, ASLN, and AIMD
Should you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include TransCode Therapeutics (RNAZ), iBio (IBIO), Shuttle Pharmaceuticals (SHPH), Tenax Therapeutics (TENX), Pulmatrix (PULM), Can-Fite BioPharma (CANF), Pasithea Therapeutics (KTTA), Universe Pharmaceuticals (UPC), ASLAN Pharmaceuticals (ASLN), and Ainos (AIMD). These companies are all part of the "pharmaceutical preparations" industry.
Processa Pharmaceuticals (NASDAQ:PCSA) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
Processa Pharmaceuticals is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.
Processa Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 222.58%. TransCode Therapeutics has a consensus target price of $480.00, indicating a potential upside of 46,958.82%. Given TransCode Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TransCode Therapeutics is more favorable than Processa Pharmaceuticals.
Processa Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of -0.36, suggesting that its stock price is 136% less volatile than the S&P 500.
Processa Pharmaceuticals received 3 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 85.71% of users gave TransCode Therapeutics an outperform vote while only 47.37% of users gave Processa Pharmaceuticals an outperform vote.
91.9% of Processa Pharmaceuticals shares are held by institutional investors. 22.2% of Processa Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of TransCode Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Processa Pharmaceuticals' return on equity of -141.42% beat TransCode Therapeutics' return on equity.
In the previous week, Processa Pharmaceuticals and Processa Pharmaceuticals both had 1 articles in the media. Processa Pharmaceuticals' average media sentiment score of 0.55 beat TransCode Therapeutics' score of 0.00 indicating that Processa Pharmaceuticals is being referred to more favorably in the media.
Summary
Processa Pharmaceuticals beats TransCode Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Processa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Processa Pharmaceuticals Competitors List
Related Companies and Tools
